AR023628A1 - Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que - Google Patents

Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que

Info

Publication number
AR023628A1
AR023628A1 ARP990102086A ARP990102086A AR023628A1 AR 023628 A1 AR023628 A1 AR 023628A1 AR P990102086 A ARP990102086 A AR P990102086A AR P990102086 A ARP990102086 A AR P990102086A AR 023628 A1 AR023628 A1 AR 023628A1
Authority
AR
Argentina
Prior art keywords
cells
agent
stimulate
increase
growth factor
Prior art date
Application number
ARP990102086A
Other languages
English (en)
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of AR023628A1 publication Critical patent/AR023628A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Abstract

Uso de un agente efectivo para incrementar el numero de células hematopoyéticas o células sanguíneas maduras de formula (1) en donde m es un entero entre 0y 10, inclusive; A y A1 son residuos L-aminoácidos (para glicina no hay dicha distincion), de manera que el A en cada unidad de repeticion entre paréntesispuede ser un residuo de aminoácido diferente; el C enlazado a B se encuentra en la configuracion L; los enlaces A y N, A1 y C, y entre A1 y N, son enlacespeptídicos; y cada X1 y X2 es, independientemente, un grupo hidroxilo o un grupo capaz de ser hidrolizado a un grupo hidroxilo en solucion acuosa a pHfisiologico, para la preparacion de un medicamento util para estimular la hematopoyesis, que comprende una cantidad efectiva de dicho agente y al menos unvehículo farmacéuticamente aceptable; uso de un agente de formula (1) para la preparacion de un medicamento util para incrementar el numero de célulashematopoyéticas o células sanguíneas maduras que acorta el tiempo en que un sujetotiene un nivel anormalmente bajo de células hematopoyéticas o sanguíneasmaduras como resultado del tratamiento de un inhibidor de células hematopoyéticas; uso de un agente de Formula (1) para preparar un medicamento util parapreparar a un sujeto para el tratamiento con un inhibidor de células hematopoyéticas donde se estimula la produccion de factor de crecimiento y dichomedicamento es para ser administrado al sujeto antes de que el sujeto reciba el inhibidor de células hematopoyéticas; métodopara estimular la produccion defactor de crecimiento por parte de células estromales, que comprende: poner en contacto células estromales con un agente en una cantidad efectiva paraestimular la produccion de factor de crecimiento por parte de las células estromales, en donde el agente es un compuesto de Formula (1); método in vitro paraestimular la produccion de factor de crecimiento por parte de células estromales, que comprende: poner en contacto células estromales con un agente en unacantidadefectiva para estimular la produccion de factor de crecimiento por parte de las células estromales, en donde el agente es un compuesto de Formula (1)
ARP990102086A 1998-05-04 1999-05-04 Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que AR023628A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8412898P 1998-05-04 1998-05-04

Publications (1)

Publication Number Publication Date
AR023628A1 true AR023628A1 (es) 2002-09-04

Family

ID=22183048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102086A AR023628A1 (es) 1998-05-04 1999-05-04 Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que

Country Status (15)

Country Link
US (4) US6300314B1 (es)
EP (1) EP1075266A1 (es)
JP (1) JP2002513762A (es)
KR (1) KR20010052302A (es)
AR (1) AR023628A1 (es)
AU (2) AU770319C (es)
BR (1) BR9910251A (es)
CA (1) CA2331122A1 (es)
IL (1) IL139247A0 (es)
MY (1) MY132924A (es)
NO (1) NO20005488L (es)
NZ (1) NZ507730A (es)
PE (1) PE20000481A1 (es)
TW (1) TWI252107B (es)
WO (1) WO1999056753A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258597B1 (en) * 1997-09-29 2001-07-10 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
JP2002513762A (ja) * 1998-05-04 2002-05-14 ポイント セラピューティクス, インコーポレイテッド 造血刺激
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
KR100915482B1 (ko) 2000-12-06 2009-09-03 하리리 로버트 제이 태반 줄기 세포의 회수 방법
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1352655A4 (en) 2001-01-16 2006-11-02 Nippon Kayaku Kk REMEDIES FOR THE TREATMENT OF BONE MARROW REMOVAL AND INFECTIOUS DISEASES AND AGENTS FOR INCREASING LEUKOCYTIC CONCENTRATION OF BLOOD
EP1362095B1 (en) * 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
AU2002360453C1 (en) * 2001-11-26 2009-06-18 The Brigham And Women's Hospital, Inc. Methods for treating autoimmune disorders, and reagents related thereto
EP2316470A3 (en) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
JP4927316B2 (ja) * 2001-12-17 2012-05-09 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 磁気共鳴方法
WO2003092605A2 (en) * 2002-04-30 2003-11-13 Trustees Of Tufts College Protease inhibitors
JP2006507352A (ja) * 2002-07-09 2006-03-02 ポイント セラピューティクス, インコーポレイテッド イソロイシンのボロプロリン化合物に関する方法および組成物
EP1571910A4 (en) 2002-11-26 2009-10-28 Anthrogenesis Corp CYTOTHERAPEUTIC AGENTS, CYTOTHERAPEUTIC UNITS AND METHODS OF TREATMENT IN WHICH THEY INTERVENE
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2524916T3 (es) * 2003-11-12 2014-12-15 Sino-Med International Alliance, Inc. Compuestos heterocíclicos de ácido borónico
BRPI0507972A (pt) * 2004-02-23 2007-07-24 Tufts College composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
WO2006052960A2 (en) * 2004-11-08 2006-05-18 The General Hospital Corporation METHODS AND COMPOSITIONS FOR INCREASING STEM CELL HOMING USING Gαs ACTIVATORS
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2452595T3 (es) 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
PL2471904T3 (pl) 2005-12-29 2019-08-30 Celularity, Inc. Populacje komórek macierzystych łożyska
US8455250B2 (en) 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008094689A2 (en) * 2007-02-01 2008-08-07 Nephrogen, Llc Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
US20080195007A1 (en) * 2007-02-12 2008-08-14 Yury Podrazhansky Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms
AU2008216749B2 (en) 2007-02-12 2014-03-13 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
US7674691B2 (en) * 2007-03-07 2010-03-09 International Business Machines Corporation Method of manufacturing an electrical antifuse
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
EP2783692B1 (en) 2007-09-28 2019-01-02 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
CN105796602A (zh) 2008-08-20 2016-07-27 人类起源公司 利用分离的胎盘细胞治疗中风
MX2011001990A (es) 2008-08-20 2011-03-29 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
CN102176919A (zh) 2008-08-22 2011-09-07 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
KR20110086176A (ko) 2008-11-19 2011-07-27 안트로제네시스 코포레이션 양막 유래 부착성 세포
CA2767014C (en) 2009-07-02 2022-01-25 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011028455A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
ES2646750T3 (es) 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
BR112012025592A2 (pt) 2010-04-06 2019-09-24 Arena Pharm Inc moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
SI2556145T1 (sl) 2010-04-07 2017-01-31 Anthrogenesis Corporation Angiogeneza z uporabo placentnih matičnih celic
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
NZ605505A (en) 2010-07-13 2015-02-27 Anthrogenesis Corp Methods of generating natural killer cells
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2753334B1 (en) 2011-08-30 2022-10-19 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
EP2814485A4 (en) 2012-02-17 2015-08-26 Merck Sharp & Dohme DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE158109C (es)
DE270382C (es)
DE296075C (es)
US4318904A (en) 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4443609A (en) 1980-05-19 1984-04-17 Petrolite Corporation Tetrahydrothiazole phosphonic acids or esters thereof
DD158109A1 (de) 1981-04-10 1982-12-29 Gunter Fischer Verfahren zur hemmung der katalytischen aktivitaet von peptidhydrolasen
US4582821A (en) 1983-11-16 1986-04-15 E. I. Du Pont De Nemours And Company Inhibition of cyclic nucleotide independent protein kinases
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4636492A (en) 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US4652552A (en) 1984-09-10 1987-03-24 E. I. Du Pont De Nemours And Company Tetrapeptide methyl ketone inhibitors of viral proteases
US4644055A (en) 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
US4664262A (en) * 1985-11-26 1987-05-12 White Pamela J Pill dispensing system
DD270382A1 (de) 1986-10-31 1989-07-26 Univ Halle Wittenberg Verfahren zur kolorimetrischen bestimmung von dipeptidylpeptidase iv mittels dipeptidhydraziden
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
EP0398880A4 (en) 1988-01-04 1990-12-27 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
DE68924850T2 (de) 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
IL91307A0 (en) 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
DE3840452A1 (de) 1988-12-01 1990-06-07 Hoechst Ag (beta)-amino-boronsaeure-derivate
DE3842197A1 (de) 1988-12-15 1990-06-21 Hoechst Ag Rasch spaltbares substrat fuer die hiv-protease
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
DD296075A5 (de) 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
DE4033062A1 (de) 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
JPH05508624A (ja) 1990-04-14 1993-12-02 ニュー イングランド メデカル センター ホスピタルズ インク ジペプチジル―アミノベプチダーゼ・4型の阻害剤
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US5378624A (en) 1990-04-23 1995-01-03 Cellpro, Incorporated Methods for removing ligands from a particle surface
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
WO1991017767A1 (en) 1990-05-21 1991-11-28 New England Medical Center Hospitals, Inc. Method of treating inhibition of dipeptidyl aminopeptidase type iv
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
FR2668069B1 (fr) * 1990-10-18 1993-02-05 Dassault Avions Dispositif, notamment autonome et portable, pour extraire de la chaleur d'une source chaude.
WO1992012140A1 (en) 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
WO1992017490A1 (en) 1991-04-04 1992-10-15 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
IE922316A1 (en) 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU2468392A (en) 1991-08-29 1993-04-05 Cytel Corporation Novel immunosuppressants
WO1993008259A2 (en) * 1991-10-22 1993-04-29 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
WO1993016102A1 (en) 1992-02-06 1993-08-19 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
WO1994003055A1 (en) 1992-07-31 1994-02-17 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
WO1994009132A1 (en) 1992-08-21 1994-04-28 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
FR2701951B1 (fr) 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2153656A1 (en) 1993-03-03 1994-09-15 Nigel Scott Cook Peptide boronic acid derivatives having protease inhibiting activity
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
AU6773994A (en) 1993-04-23 1994-11-21 Cellpro, Incorporated Methods for enriching fetal progenitor cells from maternal blood
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
FR2707170A1 (fr) 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995011689A1 (en) 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
NL9400309A (nl) 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5489025A (en) * 1994-03-01 1996-02-06 Romick; Jerome M. Unit-dose medication dispenser and multiple-dispenser frame therefor
FR2719049B1 (fr) 1994-04-22 1996-06-14 Pasteur Institut Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules.
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE4416963C1 (de) 1994-05-13 1995-07-13 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Diarylprolinolen
WO1995034538A2 (en) 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
JPH11501506A (ja) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
DE69614535T2 (de) 1995-06-07 2002-06-06 Aastrom Biosciences Inc Vorrichtung und verfahren zum aufbewahren und zur züchtung biologischer zellen
JP2000504209A (ja) * 1995-12-29 2000-04-11 エーエルジー カンパニー 骨髄間質細胞の拡大増殖
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6258597B1 (en) 1997-09-29 2001-07-10 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
JP2002513762A (ja) * 1998-05-04 2002-05-14 ポイント セラピューティクス, インコーポレイテッド 造血刺激
WO2000010549A1 (en) 1998-08-21 2000-03-02 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2006507352A (ja) 2002-07-09 2006-03-02 ポイント セラピューティクス, インコーポレイテッド イソロイシンのボロプロリン化合物に関する方法および組成物

Also Published As

Publication number Publication date
US6770628B2 (en) 2004-08-03
KR20010052302A (ko) 2001-06-25
CA2331122A1 (en) 1999-11-11
US20050037976A1 (en) 2005-02-17
AU770319B2 (en) 2004-02-19
AU770319C (en) 2004-11-25
NZ507730A (en) 2004-02-27
US20070135354A1 (en) 2007-06-14
JP2002513762A (ja) 2002-05-14
TWI252107B (en) 2006-04-01
US7067489B2 (en) 2006-06-27
BR9910251A (pt) 2001-01-02
IL139247A0 (en) 2001-11-25
WO1999056753A1 (en) 1999-11-11
US6300314B1 (en) 2001-10-09
PE20000481A1 (es) 2000-06-13
NO20005488L (no) 2001-01-04
AU2004202138A1 (en) 2004-06-10
EP1075266A1 (en) 2001-02-14
MY132924A (en) 2007-10-31
NO20005488D0 (no) 2000-10-31
US20020013279A1 (en) 2002-01-31
AU3878199A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
AR023628A1 (es) Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
ATE173924T1 (de) Zusammensetzungen für die rektale verabreichung enthaltend benzimidazole und fettsäuresalze
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
KR100355686B1 (ko) 세트로렐릭스동결건조물의제조방법
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
CA2392050A1 (en) Pharmaceutical formulations containing zolmitriptan
RU94046426A (ru) Фармацевтические композиции, способы лечения лейкоза, способ повышения уровней стволовых клеток, антагонист с - kit - лиганда, антисмысловая нуклеиновая кислота, способ лечения меланомы, способ усиления трансфекции, способ переноса гена, способ увеличения уровней периферической крови, способ повышения уровней тромбоцитов, способы модификации биологической функции, способ лечения анемии, способ улучшения приживления костного мозга, способ ускорения восстановления костного мозга, способ лечения лейкопении
JP2006504448A (ja) ペプチド銅錯体および軟組織充填物を含有する組成物
EP0047647A2 (en) Pharmaceutical compositions for promoting the healing of wounds
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
US6270750B1 (en) Proline-, glycine- and lysine-based pharmaceutical composition useful in dental treatment both in the injectable form and in the formulation for topical use
JPH10265378A (ja) 角膜上皮損傷治療剤
US6863891B2 (en) Oligopeptide lyophilisate, their preparation and use
WO1989010129A1 (en) Pharmaceutical composition containing deoxyribonucleosides for wound healing
CN1245074A (zh) 减弱阴道酸度的药剂和用途
RU2002135669A (ru) Олигопептиды
RU2005112720A (ru) Фармацевтические композиции для улучшенного введения пептидов, происходящих от gp41 вич, и их использование в терапии
Hopps et al. Demonstration and preliminary characterization of bone resorbing activity in freeze-dried gingiva of dogs
US9254306B2 (en) Eye drops
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
EP1530455B1 (en) A pharmaceutical formulation and its use in the treatment of inner ear diseases
HU892527D0 (en) Process for producing of low molecular weight prourochinase derivatives and manufacturing of pharmaceutical compositions comprising them as active ingredients
JPS60233017A (ja) 更年期障害を治療するためのゴナドリベリンおよびゴナドリベリンアゴニストの使用
EP1009345A1 (en) Skin aging and wound treatment using cell migration agents

Legal Events

Date Code Title Description
FB Suspension of granting procedure